Estonia - Kiestonia - Ravimiamet

portfarma ehf. - ropinirool - toimeainet prolongeeritult vabastav tablett - 2mg 90tk; 2mg 7tk; 2mg 100tk; 2mg 21tk; 2mg 28tk; 2mg 30tk

Estonia - Kiestonia - Ravimiamet

portfarma ehf. - ropinirool - toimeainet prolongeeritult vabastav tablett - 3mg 84tk; 3mg 42tk; 3mg 7tk; 3mg 21tk; 3mg 100tk

Estonia - Kiestonia - Ravimiamet

portfarma ehf. - ropinirool - toimeainet prolongeeritult vabastav tablett - 4mg 90tk; 4mg 7tk; 4mg 84tk; 4mg 100tk; 4mg 30tk; 4mg 28tk

Estonia - Kiestonia - Ravimiamet

pharmaceutical works polpharma s.a. - esomeprasool - süste-/infusioonilahuse pulber - 40mg 10viaal

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Estonia - Kiestonia - Ravimiamet

pharmaceutical works polpharma s.a. - orlistaat - kõvakapsel - 120mg 21tk; 120mg 42tk

Estonia - Kiestonia - Ravimiamet

pharmaceutical works polpharma s.a. - orlistaat - kõvakapsel - 60mg 42tk; 60mg 60tk; 60mg 84tk

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

acino pharma gmbh - klopidogreel - peripheral vascular diseases; stroke; myocardial infarction - antitrombootilised ained - clopidogrel on näidatud täiskasvanute ennetamise atherothrombotic sündmused:kannatavate patsientide müokardiinfarkti (paar päeva kuni vähem kui 35 päeva), ischaemic insult (7 päeva kuni vähem kui 6 kuud) või väljakujunenud perifeersete arterite haigus. täiendava teabe jaoks vt osa 5.

Estonia - Kiestonia - Ravimiamet

sopharma ad - amlodipiin - tablett - 5mg 14tk; 5mg 30tk; 5mg 28tk; 5mg 56tk; 5mg 90tk; 5mg 60tk; 5mg 50tk; 5mg 98tk

Estonia - Kiestonia - Ravimiamet

pharmaceutical works polpharma s.a. - metoprolool - toimeainet prolongeeritult vabastav tablett - 50mg 28tk; 50mg 60tk; 50mg 14tk; 50mg 56tk; 50mg 10tk